Soren F. Rasmussen

Soborg, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 90 publications

Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.

Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.

Journal: Circulation

Published: August 18, 2026

Response to Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial.

Response to Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial.

Journal: Diabetes care

Published: May 20, 2026

Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial - Authors' reply.

Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial - Authors' reply.

Journal: Lancet (London, England)

Published: March 27, 2026

Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.

Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.

Journal: JAMA internal medicine

Published: February 02, 2026

Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.

Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.

Journal: The lancet. Diabetes & endocrinology

Published: January 21, 2026

Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial.

Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial.

Journal: JAMA cardiology

Published: December 23, 2025

Nano-Gs Protein Peptidomimetics: Rational Design of Gα C-Terminus-Derived Peptides Mimicking Key Components of Gs-β2AR Interactions.

Nano-Gs Protein Peptidomimetics: Rational Design of Gα C-Terminus-Derived Peptides Mimicking Key Components of Gs-β2AR Interactions.

Journal: Angewandte Chemie (International ed. in English)

Published: October 26, 2025

Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use.

Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use.

Journal: Diabetes, obesity & metabolism

Published: July 25, 2025

Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.

Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.

Journal: European journal of heart failure

Published: April 12, 2025

Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.

Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.

Journal: Circulation

Published: March 29, 2025

Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis.

Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis.

Journal: Diabetes care

Published: February 26, 2025

Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT): Outcomes by Sex.

Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT): Outcomes by Sex.

Journal: Journal of the American College of Cardiology

Published: August 02, 2024

Showing 1-12 of 90

Last Updated: 09/26/2026